Centre for Medical Image Computing, Department of Medical Physics & Biomedical Engineering, University College London, UK.
UCL Cancer Institute, University College London, UK.
Radiother Oncol. 2020 Jul;148:89-96. doi: 10.1016/j.radonc.2020.03.026. Epub 2020 Mar 30.
Radiation-induced lung damage (RILD) is a common consequence of lung cancer radiotherapy (RT) with unclear evolution over time. We quantify radiological RILD longitudinally and correlate it with dosimetry and respiratory morbidity.
CTs were available pre-RT and at 3, 6, 12 and 24-months post-RT for forty-five subjects enrolled in a phase 1/2 clinical trial of isotoxic, dose-escalated chemoradiotherapy for locally advanced non-small cell lung cancer. Fifteen CT-based measures of parenchymal, pleural and lung volume change, and anatomical distortions, were calculated. Respiratory morbidity was assessed with the Medical Research Council (MRC) dyspnoea score and spirometric pulmonary function tests (PFTs): FVC, FEV, FEV/FVC and DLCO.
FEV, FEV/FVC and MRC scores progressively declined post-RT; FVC decreased by 6-months before partially recovering. Radiologically, an early phase (3-6 months) of acute inflammation was characterised by reversible parenchymal change and non-progressive anatomical distortion. A phase of chronic scarring followed (6-24 months) with irreversible parenchymal change, progressive volume loss and anatomical distortion. Post-RT increase in contralateral lung volume was common. Normal lung volume shrinkage correlated longitudinally with mean lung dose (r = 0.30-0.40, p = 0.01-0.04). Radiological findings allowed separation of patients with predominant acute versus chronic RILD; subjects with predominantly chronic RILD had poorer pre-RT lung function.
CT-based measures enable detailed quantification of the longitudinal evolution of RILD. The majority of patients developed progressive lung damage, even when the early phase was absent or mild. Pre-RT lung function and RT dosimetry may allow to identify subjects at increased risk of RILD.
放射性肺损伤(RILD)是肺癌放疗(RT)的常见后果,其随时间的演变尚不清楚。我们对放射学 RILD 进行了纵向定量,并将其与剂量学和呼吸发病率相关联。
45 名局部晚期非小细胞肺癌接受等毒性、剂量递增放化疗的 1/2 期临床试验患者的 RT 前和 RT 后 3、6、12 和 24 个月的 CT 均可用。计算了基于 15 项 CT 的实质、胸膜和肺容积变化以及解剖变形的指标。呼吸发病率采用改良医学研究委员会(MRC)呼吸困难评分和肺活量测定(PFT)评估:FVC、FEV、FEV/FVC 和 DLCO。
FEV、FEV/FVC 和 MRC 评分在 RT 后逐渐下降;FVC 在部分恢复前 6 个月下降。放射学上,早期(3-6 个月)的急性炎症阶段表现为可逆的实质变化和非进行性的解剖变形。随后是慢性瘢痕形成阶段(6-24 个月),表现为不可逆的实质变化、进行性容积损失和解剖变形。RT 后对侧肺容积增加很常见。正常肺容积缩小与平均肺剂量呈纵向相关(r=0.30-0.40,p=0.01-0.04)。放射学发现允许将以急性为主或慢性为主的 RILD 患者区分开来;以慢性 RILD 为主的患者在 RT 前的肺功能较差。
基于 CT 的指标可实现 RILD 纵向演变的详细定量。大多数患者出现进行性肺损伤,即使早期阶段不存在或轻微。RT 前的肺功能和 RT 剂量学可能可以识别 RILD 风险增加的患者。